Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two strengths. The approval expands Biocon’s US immunology portfolio, with Yesintek used to treat conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.